...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ,Hong Kong exchange

Hummmmmm,,,,,, I dont think you will see Zenith listed on multiple exchanges due to the inherent cost to do so and most probably not being able to meet the protocol requirments to do so on selective exchanges. It is very possible multiple listings could come to be if and when we start generating revenues. But for now we would be lucky to get a TSXV listing!!!,,,why DM has not listed us on the venture exchange at the very least is a head scratcher !!!!!!!!!!!!!!!!!,,,,,,,,,,,,,,,,,,,jmo

Share
New Message
Please login to post a reply